-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) issued an announcement. Recently, the company received a clinical trial notice for the Class 1 innovative chemical drug KC1101 tablets approved and issued by the State Drug Administration. KC1101 is a TACC3 selective small molecule inhibitor independently developed by the company. It is intended for the treatment of advanced recurrent or metastatic solid tumors.
Share
Listen to the news
Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) issued an announcement. Recently, the company received a clinical trial notice for the Class 1 innovative chemical drug KC1101 tablets approved and issued by the State Drug Administration. KC1101 is a TACC3 selective small molecule inhibitor independently developed by the company. It is intended for the treatment of advanced recurrent or metastatic solid tumors.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending